Equities research analysts predict that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will post sales of $4.23 billion for the current quarter, Zacks Investment Research reports. Eight analysts have made estimates for Teva Pharmaceutical Industries’ earnings, with the highest sales estimate coming in at $4.35 billion and the lowest estimate coming in at $4.15 billion. Teva Pharmaceutical Industries posted sales of $4.53 billion during the same quarter last year, which would indicate a negative year over year growth rate of 6.6%. The firm is expected to report its next quarterly earnings report on Thursday, November 7th.
On average, analysts expect that Teva Pharmaceutical Industries will report full year sales of $17.16 billion for the current fiscal year, with estimates ranging from $17.02 billion to $17.36 billion. For the next year, analysts forecast that the firm will post sales of $17.02 billion, with estimates ranging from $16.62 billion to $17.76 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, August 7th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 16.04% and a negative net margin of 21.94%. The firm had revenue of $4.34 billion for the quarter, compared to analysts’ expectations of $4.25 billion. During the same quarter in the previous year, the business posted $0.78 earnings per share. The business’s revenue for the quarter was down 7.7% on a year-over-year basis.
TEVA has been the topic of a number of recent analyst reports. Raymond James decreased their target price on Teva Pharmaceutical Industries from $22.00 to $15.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Mizuho set a $11.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Monday, June 17th. Oppenheimer set a $12.00 target price on Teva Pharmaceutical Industries and gave the company a “buy” rating in a research report on Wednesday, June 12th. Argus upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research report on Friday, July 5th. Finally, Zacks Investment Research cut Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a research report on Tuesday, April 23rd. Six equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $13.21.
Teva Pharmaceutical Industries stock traded down $0.14 during midday trading on Thursday, reaching $6.16. The company’s stock had a trading volume of 22,357,019 shares, compared to its average volume of 15,202,380. Teva Pharmaceutical Industries has a 52 week low of $6.07 and a 52 week high of $25.96. The company has a current ratio of 0.96, a quick ratio of 0.62 and a debt-to-equity ratio of 1.73. The business has a 50-day moving average price of $8.19 and a 200-day moving average price of $12.69. The stock has a market cap of $6.28 billion, a PE ratio of 2.20, a price-to-earnings-growth ratio of 0.73 and a beta of 1.64.
In related news, Director Sol J. Barer acquired 111,000 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were bought at an average cost of $8.98 per share, with a total value of $996,780.00. Following the completion of the purchase, the director now directly owns 115,942 shares in the company, valued at $1,041,159.16. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Notaristefani Carlo De sold 16,070 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $11.42, for a total value of $183,519.40. Following the completion of the transaction, the vice president now directly owns 49,659 shares in the company, valued at $567,105.78. The disclosure for this sale can be found here. 0.49% of the stock is owned by insiders.
Institutional investors have recently bought and sold shares of the stock. Lindbrook Capital LLC lifted its stake in shares of Teva Pharmaceutical Industries by 61.2% in the first quarter. Lindbrook Capital LLC now owns 2,489 shares of the company’s stock worth $39,000 after acquiring an additional 945 shares during the period. Cullen Frost Bankers Inc. bought a new stake in Teva Pharmaceutical Industries in the first quarter worth approximately $40,000. First Interstate Bank bought a new stake in Teva Pharmaceutical Industries in the second quarter worth approximately $28,000. Pacer Advisors Inc. bought a new stake in Teva Pharmaceutical Industries in the second quarter worth approximately $32,000. Finally, Huntington National Bank increased its holdings in Teva Pharmaceutical Industries by 88.2% in the first quarter. Huntington National Bank now owns 3,680 shares of the company’s stock worth $57,000 after purchasing an additional 1,725 shares in the last quarter. 65.28% of the stock is currently owned by institutional investors.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Recommended Story: Are sell-side analysts objective?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.